文献库搜索 | GeneLibs

Renner(AC),Kargbo(RB) ACS Med Chem Lett 2026-05-14

KRAS remains a central yet formidable oncogenic driver across multiple cancer types. Patent application WO 2026/039365 A...

Tran(K),Lavoie(H),Wahhab(A),Garrido(D),Jo(... ACS Med Chem Lett 2026-05-14

...KRAS to disrupt RAS clustering and downstream signaling. These noncovalent inhibitors bind to H/KRAS with equivalent pot...

Zhang(X),Wong(W),Cho(HS),Yang(D),Dixon(G),... Dev Cell 2026-06-10

...KRAS and TP53 mutations, whereas SMAD4 loss promotes tumor progression. Multi-omics profiling reveals epigenetic repress...

Wang(X),Liu(LL),Li(B),Jia(YJ),Li(CW),Qin(T... Zhonghua Xue Ye Xue Za Zhi 2026-04-14

...KRAS (10.3% vs 4.3% vs 2.1%, P=0.006), CBL (10.3% vs 3.4% vs 2.6%, P=0.030), ZRSR2 (10.3% vs 6.1% vs 3.2%, P=0.017), and...

Marlin(R),Colomba(E),Pennont(S),Zouzou(A),... Front Oncol None

...KRAS (18%), BRAF (4%), ERBB2 exon 20 (4%), ALK (3%), ROS1 (3%), RET (1%), NRG1 (1%), and MET exon 14 skipping (4%). PD-L...

Reynolds(J),Peng(S),Brouwer(E),Veenstra(DL... Am J Manag Care 2026-02-01

...KRAS, NTRK1/2/3, RET, ROS1, MET exon 14 skipping, and MET amplification. Seventy-seven targeted NGS panels were included...

Rodríguez Sánchez(DI),Vanneste(T),Middelko... Eur J Radiol 2026-05-00

...KRAS-only, and strictly TP53 + EGFR or TP53 + KRAS mutations were compared. Primary analyses were conducted in the origi...

Aguilar-González(A),Martos-Jamai(I),Ramos-... Nucleic Acids Res 2026-02-24

...KRAS G12D and G12C mutations, and differentiated mucocutaneous from cutaneous Leishmania sequences in analytical assays,...

Hu(Z),Sha(Z),Martí(J),Guo(SJ),Tao(SC) JACS Au 2026-02-23

KRAS is among the most frequently mutated oncogenes in human cancers, with codon 12 representing a dominant hotspot. Des...

Khan(MW),Shokry(D),Boyd(RI),Singh(R),Spine... Cancers (Basel) 2026-02-10

...KRAS signaling and the downregulation of genes normally upregulated by MYC. Focusing on genes exclusively altered in par...